The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland - BioDrugs
Source : https://link.springer.com/article/10.1007/s40259-022-00540-y
Background Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to...
Conclusions: Changes in pricing policy and the public reimbursement scheme related to the market entry of biosimilars were the main reasons for the decrease in the prices of reference products. Therefore, biosimilars did not generate genuine price competition between biological products. In many of the drug groups examined, the market shares of...
Immunological Landscape of HER-2 Positive Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35804943/
Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved...
Relevance: This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains inconsistent...
Conclusion: Real-world switch studies in oncology biosimilars that have demonstrated bioequivalence provide basis to support efficacy and safety to transition to a biosimilar product. Incorporating oncology biosimilars into treatment pathways will be an important next step in providing value-based care to patients with cancer.
Discovery of Novel Polyamide-Pyrrolobenzodiazepine Hybrids for Antibody-Drug Conjugates - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35788036/
Pyrrolobenzodiazepine (PBD) dimers are well-known highly potent antibody drug conjugate (ADC) payloads. The corresponding PBD monomers, in contrast, have received much less attention from the ADC community. We prepared several...
Relevance: “Pyrrolobenzodiazepine (PBD) dimers are well-known highly potent antibody drug conjugate (ADC) payloads. The corresponding PBD monomers, in contrast, have received much less attention from the ADC community …. Several peptide-linked variants of the lead compound were prepared and conjugated to trastuzumab to afford ADCs with...
![Drugs and Lactation Database (LactMed) [Internet].](https://static-content-prd.skipta.com/public/skipta/skipta-post/2023-02/th-lactmed-lrg_2.png "Drugs and Lactation Database (LactMed) [Internet].")
Drugs and Lactation Database (LactMed) [Internet].
Source : https://www.ncbi.nlm.nih.gov/books/NBK501373/
Filgrastim in the pharmaceutical name for granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim is the long-acting form of filgrastim. The excretion of exogenous G-CSF into breastmilk or its effects on breastfed infants...
Conclusion: Published information on the effects of filgrastim in breastmilk was not found as of the revision date. However, oral filgrastim 20 mcg daily for 5 days has been given to preterm infants with stage I necrotizing enterocolitis (NEC). Filgrastim appeared to halt progression to more severe stages of NEC in this small study.